Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1974 1
1981 1
1983 1
1986 1
1992 1
1994 2
1995 3
1996 4
1997 6
1998 5
1999 10
2000 3
2001 5
2002 6
2003 3
2004 6
2005 4
2006 7
2007 4
2008 5
2009 5
2010 1
2011 1
2012 6
2013 5
2014 2
2017 5
2018 2
2019 16
2020 9
2021 10
2022 6
2023 3
2024 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

137 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean t krahn[Author] (966 results)?
Novel adapter CAR-T cell technology for precisely controllable multiplex cancer targeting.
Seitz CM, Mittelstaet J, Atar D, Hau J, Reiter S, Illi C, Kieble V, Engert F, Drees B, Bender G, Krahl AC, Knopf P, Schroeder S, Paulsen N, Rokhvarguer A, Scheuermann S, Rapp E, Mast AS, Rabsteyn A, Schleicher S, Grote S, Schilbach K, Kneilling M, Pichler B, Lock D, Kotter B, Dapa S, Miltenyi S, Kaiser A, Lang P, Handgretinger R, Schlegel P. Seitz CM, et al. Among authors: krahl ac. Oncoimmunology. 2021 Dec 2;10(1):2003532. doi: 10.1080/2162402X.2021.2003532. eCollection 2021. Oncoimmunology. 2021. PMID: 35686214 Free PMC article.
Chimeric antigen receptor (CAR)-T therapy holds great promise to sustainably improve cancer treatment. However, currently, a broad applicability of CAR-T cell therapies is hampered by limited CAR-T cell versatility and tractability and the lack of exclusive t …
Chimeric antigen receptor (CAR)-T therapy holds great promise to sustainably improve cancer treatment. However, currently, a broad ap …
Neurostimulation for drug-resistant epilepsy.
DeGiorgio CM, Krahl SE. DeGiorgio CM, et al. Among authors: krahl se. Continuum (Minneap Minn). 2013 Jun;19(3 Epilepsy):743-55. doi: 10.1212/01.CON.0000431397.61970.2b. Continuum (Minneap Minn). 2013. PMID: 23739108 Free PMC article. Review.
Advances in Comprehensive Exposure Assessment: Opportunities for the US Military.
Krahl PL, Benchoff E, Go YM, Jones DP, Smith MR, Walker DI, Uppal K, Woeller CF, Thatcher TH, Thakar J, Phipps RP, Hopke P, Utell MJ, Mallon TM. Krahl PL, et al. J Occup Environ Med. 2019 Dec;61 Suppl 12:S5-S14. doi: 10.1097/JOM.0000000000001677. J Occup Environ Med. 2019. PMID: 31800446 Review.
CD20-CD19 Bispecific CAR T Cells for the Treatment of B-Cell Malignancies.
Martyniszyn A, Krahl AC, André MC, Hombach AA, Abken H. Martyniszyn A, et al. Among authors: krahl ac. Hum Gene Ther. 2017 Dec;28(12):1147-1157. doi: 10.1089/hum.2017.126. Hum Gene Ther. 2017. PMID: 29207878
The anti-CD20-CD19 bispecific CAR induced a full T-cell response upon engagement of CD19 or CD20 on target cells showing a true "OR" gate recognition in redirecting T-cell activation. T cells with the anti-CD20-CD19 CAR efficiently killed patients' chronic ly …
The anti-CD20-CD19 bispecific CAR induced a full T-cell response upon engagement of CD19 or CD20 on target cells showing a true "OR" …
A topological refactoring design strategy yields highly stable granulopoietic proteins.
Skokowa J, Hernandez Alvarez B, Coles M, Ritter M, Nasri M, Haaf J, Aghaallaei N, Xu Y, Mir P, Krahl AC, Rogers KW, Maksymenko K, Bajoghli B, Welte K, Lupas AN, Müller P, ElGamacy M. Skokowa J, et al. Among authors: krahl ac. Nat Commun. 2022 May 26;13(1):2948. doi: 10.1038/s41467-022-30157-2. Nat Commun. 2022. PMID: 35618709 Free PMC article.
137 results